Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis.
Nicolino RupertoHermine I BrunnerCésar Pacheco-TenaIngrid LouwGabriel Vega-CornejoAlberto J SpindlerDaniel J KingsburyHeinrike SchmelingArturo BorzutzkyRubén CutticaC J InmanVictor MalievskiyChristiaan ScottVladimir KeltsevMaria Teresa TerreriDiego Oscar ViolaRicardo M XavierTaciana A Pedrosa FernandesMaría Del Rocío Maldonado VelázquezMichael HenricksonMichael B ClarkKaren A BensleyXiaoming LiKim Hung LoJocelyn H LeuChyi-Hung HsuElizabeth C HsiaZhenhua XuAlberto MartiniDaniel J Lovellnull nullPublished in: Rheumatology (Oxford, England) (2021)
Body surface area-based dosing of i.v. golimumab was well tolerated and provided adequate PK exposure for clinical efficacy in paediatric patients with active pc-JIA.ClinicalTrials.gov number NCT02277444.
Keyphrases
- juvenile idiopathic arthritis
- open label
- ankylosing spondylitis
- disease activity
- ulcerative colitis
- phase ii
- clinical trial
- phase iii
- phase ii study
- rheumatoid arthritis
- intensive care unit
- systemic lupus erythematosus
- emergency department
- study protocol
- high dose
- squamous cell carcinoma
- double blind
- placebo controlled